Emerging research explores whether maternal use of SSRIs, antibiotics, and exposure to toxicants during pregnancy can be added to the list of established risk factors for ASD.
GLP-1 receptor agonists may better protect against cirrhosis than DPP-4 inhibitors in people who have MASLD and type 2 diabetes but early treatment is important.
Weight-neutral health strategies have gained attention as a potential alternative to weight-loss strategies for adults with obesity. This review debates the effects of these two different approaches.
GLP-1 receptor agonists and SGLT2 inhibitors have established antidiabetic and cardiovascular benefits, but could they also improve respiratory function in people with type 2 diabetes?
Diabetic macroangiopathy is a leading cause of diabetes-related mortality. Could miRNAs improve the future outlook for diabetes patients? Learn about miRNA biogenesis and their functions in diabetic macroangiopathy to find out.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.
With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report.
Genetic testing was needed to diagnose the mitochondrial disorder MIDD in a woman with diabetes, weight loss, and poor glycemic control. Glycated hemoglobin and pancreatic function improved after treatment with a DPP-4 inhibitor.
A rare case of fulminant type 1 diabetes induced by SJS/TEN, which had developed in a patient taking carbamazepine and phenytoin. Glucose monitoring should be considered for patients with SJS/TEN.
The GLP-1 receptor agonist dulaglutide was unintentionally used by a woman with type 2 diabetes until the third trimester of an unplanned and unrecognized pregnancy, but what was the outcome?
Exercise is a primary non-pharmacological intervention for managing body mass, reducing blood glucose levels, and enhancing insulin sensitivity in type 2 diabetes mellitus (T2DM) patients [ 1 ]. The recommended exercise regimen includes 150–300 min …
Diabetes is a growing pandemic and the impact of diabetes on health is projected to increase worldwide, mostly driven by increments in lower- and middle-income countries [ 1 ]. Individuals with diabetes are at an increased risk of cardiovascular …
Euglycemic ketoacidosis is an acute, life-threatening emergency that is characterized by euglycemia, metabolic acidosis, and ketonemia. It is a well-recognized adverse event in diabetic patients taking sodium-glucose cotransporter-2 inhibitor …
Metabolic syndrome is a multidimensional disorder marked by a cluster of metabolic abnormalities such as central obesity, insulin resistance, dyslipidemia, and hypertension. This condition represents a significant global health concern due to its …
Despite many recent advances in its management, type 1 diabetes remains a burden for those living with the condition.
Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.
Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills.
Stay up to date with the rapidly changing CGM landscape. Learn how to implement and integrate CGM into diabetes management to improve patient care and outcomes.
Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.
This program is not available to users in the UK and US.
Acute myocardial infarction (AMI) is the leading cause of mortality globally [ 1 ], with the incidence of non-ST segment myocardial infarction (NSTEMI), in particular, increasing [ 2 ]. Diabetes mellitus is an important risk factor for NSTEMI, with …
Type 1 diabetes is a life-long chronic autoimmune disease with an annual incidence among young people (under 20 years) of around 130,000 worldwide [ 1 ]. Its development typically runs from seroconversion (stage 1) to hyperglycaemia (stage 2), to …
Managing Inherited Metabolic Disorders (IMDs) at risk for hypoglycemia, such as Glycogen Storage Diseases (GSDs), Hereditary Fructose Metabolism Disorders (HFMDs) and Congenital Hyperinsulinism (CH), poses challenges in dietary treatments and …
Diabetes mellitus (DM) is one of the four most common chronic diseases worldwide. It currently affects around 61.4 million people in Europe, and the prognosis continues to rise [ 1 ]. A major problem is the numerous comorbidities and secondary …
Emerging research explores whether maternal use of SSRIs, antibiotics, and exposure to toxicants during pregnancy can be added to the list of established risk factors for ASD.
GLP-1 receptor agonists may better protect against cirrhosis than DPP-4 inhibitors in people who have MASLD and type 2 diabetes but early treatment is important.
Diabetic macroangiopathy is a leading cause of diabetes-related mortality. Could miRNAs improve the future outlook for diabetes patients? Learn about miRNA biogenesis and their functions in diabetic macroangiopathy to find out.
Once weekly insulin efsitora alfa reduces HbA1c by a similar amount to daily insulin degludec in people with type 2 diabetes, results of the QWINT-2 trial show.
